Breaking News Instant updates and real-time market news.

A

Agilent

$70.28

0.74 (1.06%)

, ABT

Abbott

$81.26

0.5 (0.62%)

05:55
06/11/19
06/11
05:55
06/11/19
05:55

American Diabetes Association to hold scientific sessions

79th Scientific Sessions of the ADA will be held in San Francisco on June 7-11.

A

Agilent

$70.28

0.74 (1.06%)

ABT

Abbott

$81.26

0.5 (0.62%)

AGN

Allergan

$126.65

-0.42 (-0.33%)

AMRN

Amarin

$18.08

-0.11 (-0.60%)

AMGN

Amgen

$175.58

0.04 (0.02%)

AZN

AstraZeneca

$39.59

0.57 (1.46%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$73.05

-0.93 (-1.26%)

CORT

Corcept Therapeutics

$10.06

-0.07 (-0.69%)

DRIO

DarioHealth

$0.53

0.06 (12.77%)

DXCM

DexCom

$138.42

12.32 (9.77%)

GNFT

Genfit

$23.75

-0.02 (-0.08%)

HRC

Hill-Rom

$104.31

0.88 (0.85%)

ICLR

Icon

$145.05

0.07 (0.05%)

MDT

Medtronic

$97.73

0.64 (0.66%)

MRK

Merck

$82.47

0.01 (0.01%)

NVO

Novo Nordisk

$51.22

1.85 (3.75%)

ORGO

Organogenesis

$7.35

0.14 (1.94%)

PODD

Insulet

$112.35

1.05 (0.94%)

SENS

Senseonics

$2.05

0.15 (7.89%)

SNY

Sanofi

$43.60

-0.62 (-1.40%)

SIEGY

Siemens

$0.00

(0.00%)

SRCL

Stericycle

$44.46

-0.86 (-1.90%)

TNDM

TNDM

VLRX

Valeritas

$3.60

0.13 (3.75%)

XERS

Xeris Pharmaceuticals

$8.19

-0.35 (-4.10%)

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 23

    Jun

  • 26

    Jun

  • 16

    Jul

  • 26

    Jul

  • 30

    Jul

  • 05

    Aug

  • 06

    Aug

  • 09

    Aug

  • 22

    Aug

  • 26

    Aug

  • 10

    Sep

  • 20

    Sep

  • 13

    Nov

A Agilent
$70.28

0.74 (1.06%)

05/15/19
JEFF
05/15/19
NO CHANGE
Target $85
JEFF
Buy
Agilent should be bought on today's selloff, says Jefferies
Jefferies analyst Brandon Couillard lowered his price target for Agilent Technologies to $85 from $90 following the company's "rare" miss in fiscal Q2. While the China food market recovery is taking longer, the analyst says he still sees this as a question of when and not if. Despite the "messy" "quarter and lower core growth outlook, Agilent still has a "clear pathway" to re-accelerating growth in fiscal 2020, Couillard tells investors in a research note. He recommends buying the stock on today's selloff and keeps a Buy rating on the name.
05/15/19
JPMS
05/15/19
NO CHANGE
Target $85
JPMS
Overweight
Agilent removed from Analyst Focus List at JPMorgan
JPMorgan analyst Tycho Peterson removed Agilent Technologies from his firm's Analyst Focus List following the company's fiscal Q2 results but keeps an Overweight rating on the shares with an $85 price target. Agilent reported a "surprising miss," with core growth of 4% below guidance of 5%-6% despite the easy 4.3% comp and generally solid Q1 peer results, Peterson tells investors in a research note. He attributes the miss to worse than expected headwinds from China generic pharma and food, as well as global large pharma order delays on the small-molecule side. While the miss and guidance cut were "clearly disappointing," the weakness appears driven by end market headwinds rather than competitive dynamics, and Agilent's margin expansion remains strong despite sales headwinds, says Peterson. He continues to like the stock's risk/reward at current valuation levels.
06/11/19
PIPR
06/11/19
INITIATION
Target $83
PIPR
Overweight
Agilent initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk started Agilent Technologies with an Overweight rating and $83 price target. The analyst believes the recent pullback in the shares has opened a buying opportunity. He looks for continued "strong" growth from Agilent's pharmaceutical and biotech and environmental and forensics end markets. Quirk points out the stock trades at a 19% discount to peers.
05/30/19
WOLF
05/30/19
INITIATION
Target $80
WOLF
Peer Perform
Agilent initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Agilent with a Peer Perform and $80 price target.
ABT Abbott
$81.26

0.5 (0.62%)

04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
04/18/19
LSCM
04/18/19
NO CHANGE
Target $100
LSCM
Buy
Investors should buy into Tandem Diabetes 'fire sale,' says Lake Street
Lake Street analyst Brooks O'Neil attributes the recent selloff in shares of Tandem Diabetes (TNDM) to investor fears related to the potential implications of "Medicare For All." Yesterday, the decline also appeared to "draw fuel from the strong growth" Abbott (ABT) reported for its Libre glucose monitor for diabetics, O'Neil tells investors in a research note titled "Fire Sale. Should You Buy? Yes. There Is No Fire. Affirm BUY, $100 PT." The analyst doubts the healthcare system will be changed significantly and on Libre, he says, "We're sorry, but we believe investors are either badly confused or just plain wrong." Abbott offers a low-cost version of the monitoring system but does not compete in any way with Tandem in its pump market, says the analyst. Rather, O'Neil thinks there are "potentially significant positives" for Tandem Diabetes related to the "enormous success" of Abbott's Libre franchise. The analyst sees an "extraordinarily positive" outlook for Tandem Diabetes and recommends buying the shares on the recent pullback. He affirms a Buy rating on the shares with a $100 price target.
04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
AGN Allergan
$126.65

-0.42 (-0.33%)

06/10/19
WELS
06/10/19
NO CHANGE
WELS
Evolus drug delay a positive for Allergan, says Wells Fargo
Wells Fargo analyst David Maris wrote a flash comment that Evolus' (EOLS) receiving a notice from the EC requesting supplementary information from the EMA/CHMP as part of their review of Nuceiva, a potential competitor to Botox, is a positive for Allergan (AGN), as it delays the marketing authorization application, or MAA, decision for Nuceiva in Europe. Maris kept an Outperform rating on Allergan.
05/29/19
WELS
05/29/19
NO CHANGE
Target $188
WELS
Outperform
Allergan selloff on opioid concerns an overreaction, says Wells Fargo
Wells Fargo analyst David Maris attributes the 5% selloff today in shares of Allergan (AGN) to heightened fears of opioid liability risks in the sector. Maris spoke to Allergan's investor relations team, which noted the company is fully indemnified regarding legacy Actavis generics issues. Further, Allergan has very little exposure to branded opioid sales, as they represent a very small percentage of the company's branded business, Maris tells investors in a research note. He believes the decline in Allergan shares is an overreaction to the negative headlines related to opioid-based litigation facing a number of specialty pharma companies such as Teva (TEVA), Mylan (MYL), and Mallinckrodt (MNK). Maris calls the selloff overdone and recommends buying shares of Allergan. He keeps an Outperform rating on the name with a $188 price target.
06/11/19
LEHM
06/11/19
INITIATION
Target $133
LEHM
Underweight
Allergan initiated with an Underweight at Barclays
Barclays analyst Balaji Prasad started Allergan with an Underweight rating and $133 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
05/28/19
GSCO
05/28/19
INITIATION
Target $154
GSCO
Neutral
Allergan initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Allergan with a Neutral rating and $154 price target. The analyst finds the company's non-migraine pharma pipeline "generally underwhelming" and believes its leverage profile "somewhat limits" its capital allocation flexibility.
AMRN Amarin
$18.08

-0.11 (-0.60%)

04/29/19
JEFF
04/29/19
NO CHANGE
Target $30
JEFF
Buy
Amarin settlement could be 'key catalyst' for shares, says Jefferies
Recent updates in the dosing patent litigation between Amarin (AMRN) and Hikma and Reddy's show the sides have been progressing and both cases were moved under the same judge in Nevada, Jefferies analyst Michael Yee tells investors in a research note. The analyst believes uncertainty around the ongoing litigation presents a risk for investors and that there is a perception on the Street that the cases impactsany potential acquisition transaction for Amarin until there is clarity. With Judge Du setting a trial date for January 13, 2020, at least a timeline for one of the two major cases is known, Yee writes. He believes a potential "key catalyst" could be a settlement beforehand. The analyst continues to think another settlement, like the one Amarin reached with Teva (TEVA), and removal of the overhang is "likely in time and is a win-win for all parties." This "could be quite important" for Amarin shares, says Yee. He keeps a Buy rating on Amarin with a $30 price target.
05/02/19
SBSH
05/02/19
NO CHANGE
Target $23
SBSH
Buy
Amarin selloff creates attractive entry point, says Citi
Citi analyst Joel Beatty believes the selloff yesterday in shares of Amarin (AMRN) brings an attractive entry point. He raised his price target for the stock to $23 from $20 and keeps a Buy rating on the name. The analyst sees five potential upside catalysts this year, including a likely supportive ICER cost-effectiveness review and potential priority review from the FDA. Further, while an acquisition of Amarin is possible, the company acquiring The Medicines Co. (MDCO) or Esperion (ESPR) "could also be a viable path," says Beatty.
05/29/19
CANT
05/29/19
NO CHANGE
Target $35
CANT
Overweight
Amarin Priority Review could drive upside to estimates, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that because of this morning's Priority Review designation, the timing of the FDA action date for Vascepa is four months earlier than the anticipated standard ten-month review for applications. Amarin had been assuming a standard ten-month review, and so has the Street, Chen tells investors in a research note. As such, she believes this morning's news, as well as the "positive" year-over-year prescription trends could drive upside to consensus estimates in 2019 and beyond. The analyst keeps an Overweight rating on Amarin shares with a $35 price target.
05/17/19
BTIG
05/17/19
INITIATION
Target $5
BTIG
Buy
Matinas BioPharma initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Matinas BioPharma (MTNB) with a Buy rating and $5 price target, noting that the company's lead candidate, MAT9001, showed superior TG lowering versus Amarin's(AMRN) Vascepa. He thinks the Omega 3 class can have multiple winners and estimates MAT9001 peak revenue of greater than $2B.
AMGN Amgen
$175.58

0.04 (0.02%)

06/05/19
HCWC
06/05/19
NO CHANGE
Target $117
HCWC
Buy
Mirati Therapeutics price target raised to $117 from $84 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics (MRTX) to $117 from $84 saying the positive data for Amgen's (AMGN) AMG 510 bode well for Mirati's MRTX849. The analyst believes the AMG 510 data "somewhat derisks" the development of MRTX849/ He raised his estimate for probability of success for MRTX849 to 20% from 10% and keeps a Buy rating on Mirati Therapeutics.
06/05/19
LEHM
06/05/19
NO CHANGE
Target $123
LEHM
Overweight
Mirati Therapeutics price target raised to $123 from $85 at Barclays
Barclays analyst Gena Wang raised her price target for Mirati Therapeutics (MRTX) to $123 from $85 saying Amgen's (AMGN) AMG510 data support KRAS G12C as a validated target, and the "impressive" data provide proof of concept for potentially single agent activity in non-small cell lung cancer. The analyst continues to believe that Mirati's MRTX849 could have a more favorable profile based on the preclinical results, including "longer half-life and good tissue penetration." She reiterates an Overweight rating on Mirati Therapeutics.
06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Mirati to Neutral following near-tripling of stock
As previously reported, Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics (MRTX) to Neutral from Buy, noting that the shares have nearly tripled since data were presented at the European Society for Medical Oncology, or ESMO, meeting in October. While Schmidt said Amgen's (AMGN) KRAS inhibitor Phase I data presented at the American Society of Clinical Oncology meeting validates MRTX849's potential mechanism of action, he sees a "lot of upside" priced in at the current valuation despite the remaining development risks. He also believes investor expectations have significantly increased ahead of Mirati's own Phase I data presentation in the second half of the year.
06/04/19
RHCO
06/04/19
NO CHANGE
Target $120
RHCO
Buy
Mirati Therapeutics price target raised to $120 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics (MRTX) to $120 and kept his Buy rating following yesterday's "encouraging" ASCO presentation by Amgen (AMGN) regarding its KRAS G12C inhibitor AMG 510. The analyst notes that the side effect profile and response to the treatment's lowest dose in AMG 510 are positive for Mirati's MRTX849, raising his probability Adjusted Peak Sales for the latter to $1.65B from $1.33B with probability of success little changed at 52%.
AZN AstraZeneca
$39.59

0.57 (1.46%)

05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
03/31/19
DBAB
03/31/19
DOWNGRADE
DBAB
Hold
Bayer downgraded to Hold from Buy at Deutsche Bank
03/21/19
03/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Market Perform from Outperform at Wells Fargo after the company reported the failure of two phase 3 trials for a potential treatment of Alzheimer's disease. 2. Magna (MGA) downgraded to Market Perform from Outperform at BMO Capital with analyst Peter Sklar noting BMW's (BMWYY) lowered 2019 earnings guidance on numerous headwinds reflects how difficult it is for auto manufacturers to grow earnings during a period of flat to declining vehicle production volumes. 3. Munich Re (MURGY) downgraded to Hold from Buy at Jefferies with analyst Philip Kett saying he believes the recent rally leaves less room for valuation upside. 4. Nufarm (NFRMY) downgraded to Neutral from Overweight at JPMorgan with analyst Donald Carducci noting glyphosate is becoming a concern for Bayer (BAYRY) due to a recent U.S. case progressing to phase two. 5. Micron (MU) downgraded to Sell from Neutral at Citi with analyst Christopher Danely saying Micronis trying its best but "you can't swim against a tsunami". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
BREN
04/01/19
DOWNGRADE
BREN
Hold
Bayer resumed with a Hold from Buy at Berenberg
Berenberg transferred coverage of Bayer to analyst Sebastian Bray and downgraded the stock to Hold from an under review designation. The analyst sees downside from legal settlements following the unfavorable glyphosate verdicts. He has a price target of EUR 67 for the shares.
CL Colgate-Palmolive
$73.05

-0.93 (-1.26%)

04/29/19
JPMS
04/29/19
UPGRADE
Target $70
JPMS
Neutral
Colgate-Palmolive upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Colgate-Palmolive to Neutral from Underweight and raised her price target for the shares to $70 from $62.
04/29/19
JEFF
04/29/19
NO CHANGE
Target $73
JEFF
Hold
Colgate-Palmolive price target raised to $73 from $61 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Colgate-Palmolive to $73 from $61 following the company's "solid" Q1 results. While a recovery in China will take time, Colgate-Palmolive is "importantly seeing progress" across key markets, including the U.S. and Latin America, and the Colgate Total relaunch is progressing in-line with expectations, Grundy tells investors in a research note. He views the company's sales recovery as "encouraging," but thinks the stock's current valuation limits upside potential. As such, he keeps a Hold rating on Colgate-Palmolive.
04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/29/19
JPMS
04/29/19
UPGRADE
Target $70
JPMS
Neutral
JPMorgan upgrades Colgate-Palmolive to Neutral on improved sales growth
JPMorgan analyst Andrea Teixeira upgraded Colgate-Palmolive to Neutral from Underweight and raised her price target for the shares to $70 from $62. The company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S., Teixeira tells investors in a research note. For the first time in two years, Colgate-Palmolive delivered both volume and pricing growth when reporting quarterly results on Friday, says the analyst. She notes that while the company's global market share losses on a year-over-year basis are still lingering, its market share has been more stable sequentially.
CORT Corcept Therapeutics
$10.06

-0.07 (-0.69%)

02/01/19
RILY
02/01/19
DOWNGRADE
RILY
Neutral
Corcept Therapeutics downgraded to Neutral from Buy at B. Riley FBR
02/01/19
RILY
02/01/19
DOWNGRADE
Target $12
RILY
Neutral
B. Riley FBR downgrades Corcept to Neutral on Q4 sales miss
B. Riley FBR analyst David Buck downgraded Corcept Therapeutics to Neutral from Buy and cut his price target for the shares to $12 from $22. The analyst cites the company's "disappointing" preliminary Q4 sales for the downgrade. The stock in midday trading is down 10%, or $1.16, to $10.02.
02/01/19
CANT
02/01/19
DOWNGRADE
Target $14
CANT
Neutral
Corcept Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan downgraded Corcept Therapeutics to Neutral and lowered his price target for the shares to $14 from $20. The company's lower than projected Korlym revenue for Q4 and 2019 guidance points to limited upside potential, Duncan tells investors in a post-earnings research note. Further, the analyst says investors need visibility on relacorilant.
02/05/19
RILY
02/05/19
NO CHANGE
Target $12
RILY
Neutral
Corcept overhang unlikely to lift despite 'helpful' response, says B. Riley FBR
B. Riley FBR analyst David Buck reiterates a Neutral rating on shares of Corcept Therapeutics with an $11 price target following another short seller report as well as response from the company. Negative commentary from short-seller reports have raised a number of issues, including off-label promotion, bribing physicians through speaker fees or otherwise to prescribe Korlym, questioning the efficacy of Korlym and using the FDA's adverse event reporting database to taint the drug as dangerous, and the possible overstatement of sales from the Veteran's Administration channel, Buck tells investors in an intraday research note. He believes Corcept's response this morning to the allegations is "helpful," but he does not expect the overhang to lift immediately from the shares. The stock in midday trading is up 3%, or 32c, to $10.52.
DRIO DarioHealth
$0.53

0.06 (12.77%)

06/06/19
CHLM
06/06/19
INITIATION
Target $1.5
CHLM
Buy
DarioHealth initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alex Nowak initiated DarioHealth with a Buy rating and $1.50 price target, calling the stock the only public "pure-play" on digital therapeutics for Type 2 Diabetes.
DXCM DexCom
$138.42

12.32 (9.77%)

04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees Q1 revenue upside for Inogen, Teleflex, Align Technology
Piper Jaffray analyst Matt O'Brien says his deep dive into the MedTech companies exploring the direct-to-consumer sales channel came up "most compelling" for Inogen (INGN), Teleflex (TFX) and Align Technology (ALGN). Website traffic at these companies is at or near three-year highs and historical trends suggest a high likelihood of revenue upside in Q1, O'Brien tells investors in a research note. The analyst also found DexCom's (DXCM) website traffic to be at three-year highs.
05/02/19
JPMS
05/02/19
NO CHANGE
Target $170
JPMS
Overweight
DexCom raised guidance still looks conservative, says JPMorgan
JPMorgan analyst Robbie Marcus believes DexCom posted "another impressive quarter" and that its raised guidance still looks conservative. The analyst lowered his price target for the shares to $170 from $175 with peer multiples moving down year-to-date, but he continues to recommend the name with an Overweight rating.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $173
PIPR
Overweight
DexCom price target raised to $173 from $165 at Piper Jaffray
Piper Jaffray analyst JP Kim raised his price target on DexCom to $173 and kept his Overweight rating after its "solid" Q1 results. The analyst notes that while the company's Q1 gross margin of 60% was below his expected 64.5% amid capacity expansion investments, he sees DexCom well positioned for the "inflection" in the Continuous Glucose Monitoring market as it converts away from Blood Glucose Meters. Kim also cites the management's discussion of pharmacy contracts having a 2-3 year time span and expects the company's G7 system tracking to launch next year to be competitive "at any price point."
GNFT Genfit
$23.75

-0.02 (-0.08%)

04/22/19
HCWC
04/22/19
NO CHANGE
Target $72
HCWC
Buy
Genfit price target lowered to $72 from EUR 105 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Genfit to $72 from EUR 105 citing the impact of the 24.5% share dilution from the company's recent global offering. The new target, however, still represents about 188% upside from current levels and an implied market capitalization of $2.8B, Arce tells investors in a research note. With Genfit's Nasdaq listing complete, investor focus sharpens on nonalcoholic steatohepatitis and primary biliary cholangitis, adds the analyst. He keeps a Buy rating on the stock.
04/24/19
LEER
04/24/19
INITIATION
Target $58
LEER
Outperform
Genfit initiated with an Outperform at SVB Leerink
SVB Leerink analyst Pasha Sarraf started Genfit with an Outperform rating and $58 price target. The analyst's core thesis in obesity-induced metabolic liver diseases, including nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, is the utility of combining therapies that provide metabolic, and anti-inflammatory/fibrotic benefits on a background of practical weight loss therapies. Genfit's elafibranor may become one of the first products entering the market that fits this thesis with reproducibly meaningful lipid and triglyceride lowering benefits, insulin sensitization and reduction of glycated hemoglobin, and impact on inflammatory hepatic pathology, Sarraf tells investors in a research note.
05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Genfit after positive recommendation from DSMB
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $72 price target on Genfit after the company announced that the the Data Safety Monitoring Board, or DSMB, of the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of NASH, or nonalcoholic steatohepatitis, had "rendered a positive recommendation for the trial's continuation without any changes. This 36-month safety review is the sixth planned review by the DSMB, and revealed no safety issues with elafibranor." The analyst estimates elafibranor's probability of success at 75% for NASH and 60% for PBC, and utilize a 11.5% discount rate, which he believes is "appropriate for a small-cap development stage biotech."
04/22/19
LEHM
04/22/19
INITIATION
Target $55
LEHM
Overweight
Genfit initiated with an Overweight at Barclays
Barclays analyst Geoff Meacham started Genfit with an Overweight rating and $55 price target. Despite the challenges in nonalcoholic steatohepatitis, Genfit's pipeline offers "compelling opportunities," which creates an attractive risk/reward profile for the stock, Meacham tells investors in a research note.
HRC Hill-Rom
$104.31

0.88 (0.85%)

10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
Hill-Rom initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated Hill-Rom with an Equal Weight rating and $95 price target.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Buy
Hill-Rom initiated with a Buy at UBS
UBS analyst Matthew Taylor initiated Hill-Rom with a Buy rating and $115 price target, calling the stock a Top Buy for Quality?FCF/Value. Taylor said Hill-Rom's "revenue growth is underestimated" and noted that the company's "portfolio moves have added more recurring revenue in higher growth markets."
07/17/18
KEYB
07/17/18
NO CHANGE
Target $115
KEYB
Overweight
Hill-Rom price target raised to $115 from $97 at KeyBanc
KeyBanc analyst Matthew Mishan raised his price target for Hill-Rom to $115 from $97 as he believes investors could grow increasingly confident in an improved long-term growth outlook. The analyst reiterates an Overweight rating on the shares.
ICLR Icon
$145.05

0.07 (0.05%)

01/25/19
MZHO
01/25/19
UPGRADE
Target $150
MZHO
Buy
Icon upgraded to Buy from Neutral at Mizuho
Mizuho analyst Ann Hynes upgraded Icon to Buy and raised her price target for the shares to $150 from $146. The recent volatility in the Contract Research Organization group provides a "nice entry point" into Icon shares, Hynes tells investors in a research note. She prefers Icon to the other CROs due to the "quality" of its earnings, "strong" cash conversion, and potential for earnings upside versus its peers.
04/02/19
WOLF
04/02/19
INITIATION
Target $149
WOLF
Outperform
Icon initiated with an Outperform at Wolfe Research
Wolfe Research initiated Icon with an Outperform and $149 price target to reflect leverage growth and share underperformance.
02/25/19
RHCO
02/25/19
NO CHANGE
Target $161
RHCO
Buy
Icon price target raised to $161 from $150 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Icon to $161 and kept his Buy rating after its Q4 earnings beat, maintained 2019 guidance, and strong book-to-bill. The analyst believes that the consensus for the company's earnings can move higher through the year end, driven by Icon's rising operating leverage from flat SG&A expenses and stock buybacks.
06/11/19
MZHO
06/11/19
NO CHANGE
Target $160
MZHO
Buy
Icon price target raised to $160 from $154 at Mizuho
Mizuho analyst Ann Hynes raised her price target for Icon to $160 from $154 and reiterates a Buy rating on the shares after hosting meetings with management. The analyst remains positive on Icon citing the "good" industry backdrop, "strong" organic revenue growth trends, quality and its "consistency" of earnings. Icon is the analyst's top pick in the Contract Research Organization space.
MDT Medtronic
$97.73

0.64 (0.66%)

06/04/19
WELS
06/04/19
UPGRADE
Target $110
WELS
Outperform
Wells Fargo upgrades Medtronic to Outperform with $110 price target
Wells Fargo analyst Lawrence Biegelsen upgraded Medtronic to Outperform from Market Perform and raised his price target for the shares to $110 from $100. The stock closed today up $1.08 to $94.41. The analyst says the company's late stage pipeline will accelerate its growth into fiscal 2021. Further, management has done a better job over the past year of managing consensus expectations, Biegelsen tells investors in a research note. Medtronic is an "accelerating growth story trading at a steep discount to peers," adds the analyst, who sees the valuation gap closing as its growth picks up.
06/04/19
WELS
06/04/19
UPGRADE
Target $110
WELS
Outperform
Medtronic upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen upgraded Medtronic to Outperform from Market Perform and raised his price target for the shares to $110 from $100.
06/05/19
06/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Roku (ROKU) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris saying he sees "strong secular tailwinds" for streaming video consumption and believes the company's Q1 results were representative of the core trajectory for its key metrics. 2. Cronos Group (CRON) double upgraded to Buy from Underperform at BofA/Merrill with analyst Christopher Carey saying he has improved confidence that Cronos is near announcing a launch in the U.S., following recent comments by management. 3. Medtronic (MDT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Lawrence Biegelsen saying the company's late stage pipeline will accelerate its growth into fiscal 2021. 4. e.l.f. Beauty (ELF) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Dara Mohsenian saying he views valuation as more reasonable following the 53% drop in the stock over the last year. 5. FleetCor (FLT) and Wex (WEX) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/28/19
RBCM
05/28/19
NO CHANGE
Target $100
RBCM
Outperform
Medtronic price target lowered to $100 from $109 at RBC Capital
RBC Capital analyst Brandon Henry lowered his price target on Medtronic to $100 to reflect his lowered FY20 revenue forecast to $31.3B from $31.6B on updated expectations for FX and Cardio Vascular business after its Q4 results and Q1 earnings guidance. The analyst also keeps his Outperform rating on the shares, citing the company's organic growth outlook of "at least 4%" through FY22. Henry further expects Medtronic's therapy innovations to contribute about half of the company's revenue growth.
MRK Merck
$82.47

0.01 (0.01%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.
NVO Novo Nordisk
$51.22

1.85 (3.75%)

04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Guggenheim sees limited upside for Eli Lilly, downgrades to Neutral
As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has "the best long-term growth profile in US Pharma," that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
04/30/19
PART
04/30/19
DOWNGRADE
PART
Hold
Novo Nordisk downgraded to Hold from Buy at Pareto
04/29/19
FBCO
04/29/19
UPGRADE
FBCO
Outperform
Novo Nordisk upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Trung Huynh upgraded Novo Nordisk to Outperform from Neutral with an increased price target of DKK 360. Novo would likely be a "key beneficiary" of U.S. healthcare reform if it's enacted, Huynh tells investors in a research note. The analyst sees accelerating growth momentum for the company.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
ORGO Organogenesis
$7.35

0.14 (1.94%)

04/17/19
04/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Organogenesis (ORGO) initiated with an Outperform at Oppenheimer. 2. Teladoc (TDOC) initiated with an Overweight at Stephens. 3. Solar Capital (SLRC) initiated with an Outperform at Raymond James. 4. Principia Biopharma (PRNB) initiated with a Buy at Stifel. 5. Aurora Cannabis (ACB), HEXO Corp (HEXO), Canopy Growth (CGC), and Performance Food Group (PFGC) initiated with a Buy at BofA/Merrill while Cronos Group (CRON) was initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/19
OPCO
04/16/19
INITIATION
Target $11
OPCO
Outperform
Oppenheimer starts 'regenerative medicine story' Organogenesis at Outperform
Oppenheimer analyst Steven Lichtman initiated coverage of Organogenesis with an Outperform rating and $11 price target. The company has a "diverse product set at different levels of complexity and price points that address a wide spectrum of wounds and musculoskeletal injuries," Lichtman tells investors in a research note. The analyst sees Organogenesis' markets as growing more than high-single digits and not highly penetrated. He calls the company as a "well-positioned regenerative medicine story."
04/16/19
OPCO
04/16/19
INITIATION
Target $11
OPCO
Outperform
Organogenesis initiated with an Outperform at Oppenheimer
Oppenheimer initiated Organogenesis with an Outperform and $11 price target.
05/02/19
FBCO
05/02/19
INITIATION
Target $9
FBCO
Outperform
Organogenesis initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic started coverage of Organogenesis with an Outperform rating and a $9 price target. The analyst notes that the company has assembled an "impressive" portfolio of regenerative medicine and differentiated products in key growth segments within wound care. His positive view is based on a clear opportunity to gain share in the high-value, high-growth amniotic tissue segment; sustainable double-digit growth, adjusting for upcoming reimbursement changes; and improving margins driven by mix and improving operating leverage.
PODD Insulet
$112.35

1.05 (0.94%)

06/10/19
NORL
06/10/19
DOWNGRADE
NORL
Market Perform
Insulet downgraded to Market Perform from Outperform at Northland
Northland analyst Suraj Kalia downgraded Insulet to Market Perform from Outperform.
06/10/19
06/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cheniere Energy Partners (CQP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying while she views the company's positive FID on Train 6 and updated run-rate guidance positively, she believes these announcements were in line with expectations. 2. At Home Group (HOME) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Simeon Gutman saying after the company's recent earnings miss and guidance cut that its headwinds appear less transitory than he'd previously thought. 3. Lazard (LAZ) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the company's pipeline of advisory revenue has been "weak." 4. Insulet (PODD) downgraded to Market Perform from Outperform at Northland with analyst Suraj Kalia citing valuation. 5. Realogy (RLGY) downgraded to Equal Weight from Overweight at Stephens with analyst John Campbell saying he believes the company will sees a "depressed multiple" until it can prove the sustainability of its model, which he thinks will take at least a few quarters of consistent earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
ADAM
05/06/19
NO CHANGE
Target $110
ADAM
Buy
Insulet price target raised to $110 from $100 at Canaccord
Canaccord analyst Kyle Rose raised his price target for Insulet to $110 from $100 and maintained a Buy rating following last week's Q1 earnings report. In a research note to investors following the earnings report, Rose said he continues to believe Insulet is positioned favorably ahead of what he views as a compelling new product cycle in Dash.
06/10/19
NORL
06/10/19
DOWNGRADE
NORL
Market Perform
Insulet downgraded to Market Perform on valuation at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Insulet to Market Perform from Outperform, calling the rating change "simply a valuation call." He sees no major catalyst for shares in the short-term and thinks "slight revenue beats" over the next few quarters are priced into the stock at current levels, the analyst tells investors.
SENS Senseonics
$2.05

0.15 (7.89%)

06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Senseonics receives FDA claim for Eversense CGM system, says Piper Jaffray
Piper Jaffray analyst JP McKim maintained a Neutral rating and $2.70 price target on Senseonics, while noting that the company "received a non-adjunctive claim for their Eversense CGM system" from the FDA. The analyst said that the claim would allow Eversense "to be used in replacement for finger stick glucose measurements" and added that it "is a needed claim to begin the process to unlock the Medicare population and represents an important stage in their commercialization process."
01/29/19
PIPR
01/29/19
INITIATION
Target $2.7
PIPR
Neutral
Senseonics initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst JP McKim started Senseonics with a Neutral rating and $2.70 price target. The analyst believes the stock's risk/reward remains balanced over the next 12 months given the "hand to hand combat of reimbursement coverage and at its current 90 day configuration in the U.S."
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Sell
Senseonics initiated with a Sell at UBS
UBS analyst Matthew Taylor initiated Senseonics with a Sell rating and $2 price target, calling the stock a Top Sell. Taylor said he sees risks to the downside given his view that "Eversense is a niche product and competition is improving."
02/04/19
PIPR
02/04/19
NO CHANGE
Target $2.7
PIPR
Neutral
Piper Jaffray uncertain of benefits from increased Roche access for Senseonics
Piper Jaffray analyst JP Kim kept his Neutral rating and $2.70 price target on Senseonics (SENS) after the company announced an extension of agreement with Roche (RHHBY). The analyst notes that the management is likely willing to trade off the near term price gains for long term volume gain through this deal, but adds that a reset of consensus estimates for sales that would lead to Senseonics becoming a "beat and raise story" is uncertain.
SNY Sanofi
$43.60

-0.62 (-1.40%)

05/08/19
BMOC
05/08/19
NO CHANGE
Target $375
BMOC
Market Perform
Regeneron price target lowered to $375 from $412 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron (REGN) to $375 after its "uninspiring" Q1 driven by higher R&D costs and lower collaboration revenue with Sanofi (SNY). The analyst notes that while the company's Dupixent is "showing progress" and Eylea's 8% revenue growth is a positive, he is also concerned with higher discounting for the latter along with the potential for a more competitive vascular endothelial growth factor, or VEGF, landscape. Luchini keeps his Market Perform rating on Regeneron.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
SIEGY Siemens
$0.00

(0.00%)

05/21/19
FBCO
05/21/19
UPGRADE
FBCO
Outperform
Siemens upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andre Kukhnin upgraded Siemens to Outperform from Neutral and raised his price target for the shares to EUR 143 from EUR 115.
01/15/19
RBCM
01/15/19
INITIATION
RBCM
Sector Perform
Siemens initiated with a Sector Perform at RBC Capital
02/26/19
JPMS
02/26/19
UPGRADE
JPMS
Overweight
Siemens upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andreas Willi upgraded Siemens to Overweight and raised his price target for the shares to EUR 118 from EUR 115. The analyst sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." Siemens needs to adjust its Vision 2020+ strategy at the May meeting and reassure investors and provide substantiation of what will change, Willi tells investors in a research note.
02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SRCL Stericycle
$44.46

-0.86 (-1.90%)

03/22/19
BMOC
03/22/19
NO CHANGE
Target $50
BMOC
Market Perform
Stericycle price target raised to $50 from $45 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on Stericycle to $50 after his meeting with its management, saying the company's business transformation appears to be progressing. While it will take time to play out, the analyst believes that the company's Enterprise Resource Planning and portfolio rationalization efforts are on the right track. Shorter term, Silber keeps his Market Perform rating on Stericycle, noting that while "the company's diversification has reduced some health care end-market risk", its medical waste end market is still facing issues around pricing pressures and industry consolidation.
04/10/19
STFL
04/10/19
NO CHANGE
Target $70
STFL
Buy
Stericycle sees 'realistic potential' for sustainable growth, says Stifel
After traveling with incoming Stericycle CEO Cindy Miller, Stifel analyst Michael Hoffman noted that she expects to become a sustainable, scalable growth company after making Stericycle smaller and leaner, but said that Miller "is not interested in shrinking to greatness." Stericycle's business model is not broken, but it must re-establish it can repeatedly predict its outlook, said Hoffman, who reaffirmed his Buy rating and $70 target price on the stock following the management meeting.
04/17/19
BARD
04/17/19
DOWNGRADE
BARD
Underperform
Stericycle downgraded to Underperform from Neutral at Baird
04/18/19
BARD
04/18/19
DOWNGRADE
Target $44
BARD
Underperform
Stericycle downgraded to Underperform from Neutral at Baird
Baird analyst David Manthey downgraded Stericycle to Underperform from Neutral and maintained a $44 price target, telling investors in a research note that he believes sentiment is "overly optimistic." Manthey says new management and reduced guidance "do not represent the solution," but rather the starting point of a "long road," and while he can envision a path to $80+ in 2023, it is "not an easy one." He thinks "demonstrably" better results will be years away and investors are "whistling past a myriad" of lingering issues.
TNDM TNDM

05/01/19
OPCO
05/01/19
NO CHANGE
Target $80
OPCO
Outperform
Tandem Diabetes price target raised to $80 from $68 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $80 from $68 as its Q1 sales of $66M were well above his/Street's expectations, led by strong U.S. pump shipments, and continued international expansion. Heading into 2020, the analyst expects new drivers to build, namely increased pump renewal contribution, Control-IQ launch and t:sport introduction. He reiterates an Outperform rating on the shares.
05/01/19
CHLM
05/01/19
NO CHANGE
Target $84
CHLM
Buy
Tandem Diabetes price target raised to $84 from $70 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Tandem Diabetes to $84 from $70 as results again surpassed the Street's estimates and the company raised guidance. The analyst reiterates a Buy rating on the shares.
05/13/19
PIPR
05/13/19
NO CHANGE
Target $78
PIPR
Overweight
Tandem Diabetes' 'rapid' growth can continue, says Piper Jaffray
Piper Jaffray analyst JP McKim reiterates an Overweight rating on Tandem Diabetes with a $78 price target after traveling with management. The company can continue its "rapid" growth though international expansion beyond Animas patients, McKim tells investors in a research note titled "Travel With Management Confirms 'Goldilocks Period' Set To Continue." Further, while Animas supplies stop September 2019, there will be patients who stock up on supplies into 2020 and also some of the patients who took the free MDT 630G in late 2017 will have their old Animas warranty expire and allow them to re-enter the pump market once again, adds the analyst. He also expects Tandem win market share.
05/13/19
LEER
05/13/19
INITIATION
Target $83
LEER
Outperform
Tandem Diabetes initiated with an Outperform at SVB Leerink
SVB Leerkink analyst Danielle Antalffy initiated Tandem Diabetes with an Outperform and $83 price target.
VLRX Valeritas
$3.60

0.13 (3.75%)

07/05/18
OPCO
07/05/18
INITIATION
Target $3.5
OPCO
Outperform
Valeritas initiated with an Outperform at Oppenheimer
Oppenheimer analyst Steven Lichtman started Valeritas with an Outperform rating and $3.50 price target, citing its unique insulin delivery system, large market opportunity and drivers ahead.
12/04/18
BTIG
12/04/18
INITIATION
Target $1
BTIG
Buy
Valeritas initiated with a Buy at BTIG
BTIG analyst Sean Lavin initiated Valeritas with a Buy rating and a price target of $1.00. The analyst is positive on the "simple design, low cost, and demonstrated clinical benefits" of its V-Go basal-bolus insulin pump and believes that the company is in the best shape since it launched the product in 2012, having met its capital needs for the next 2-3 years with the recent capital raise. Lavin adds that the selling strategy of Valeritas is gaining momentum while its gross margins are expanding.
07/05/18
07/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Deciphera (DCPH) initiated with a Buy at SunTrust. 2. EQT Corporation (EQT) initiated with a Hold at TD Securities. 3. Pioneer Natural (PXD) initiated with a Buy at TD Securities. 4. Veoneer (VNE) initiated with an Overweight at Barclays. 5. Valeritas (VLRX) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
XERS Xeris Pharmaceuticals
$8.19

-0.35 (-4.10%)

06/07/19
MZHO
06/07/19
NO CHANGE
Target $27
MZHO
Buy
Xeris selloff on PDUFA extension a buying opportunity, says Mizuho
Mizuho analyst Difei Yang recommends buying shares of Xeris Pharmaceuticals on weakness from the extension of the FDA action date for Gvoke. The delay is not material, and a number of PDUFA goal date extensions for drug applications have concluded with product approvals, Yang tells investors in a research note. The analyst would buy shares of Xeris, "especially on recent weakness," and reiterates a Buy rating on the name with a $27 price target.
07/16/18
MZHO
07/16/18
INITIATION
Target $26
MZHO
Buy
Xeris Pharmaceuticals initiated with a Buy at Mizuho
Mizuho initiated Xeris Pharmaceuticals with a Buy and $26 price target.
07/17/18
MZHO
07/17/18
INITIATION
Target $26
MZHO
Buy
Mizuho starts Xeris Pharmaceuticals with Buy rating, $26 target
Mizuho analyst Difei Yang last night initiated coverage of Xeris Pharmaceuticals with a Buy rating and $26 price target. The company offers a potentially superior solution for the treatment of severe hypoglycemia compared to the standard of care - Eli Lilly's (LLY) glucagon emergency kit, Yang told investors in a research note. The analyst sees a "significant growth opportunity" for the ready-to-use glucagon rescue pen as more healthcare professionals prescribe an easier option for patients with diabetes at risk of severe hypoglycemia.
09/13/18
EAMC
09/13/18
INITIATION
Target $10
EAMC
Sell
Xeris Pharmaceuticals initiated with a Sell at Empire
Empire analyst Dr. Cathey Reese initiated Xeris Pharmaceuticals with a Sell and $10 price target saying its main pipeline product is a stable liquid glucagon in an autoinjector device, which the company filed for an FDA approval in mid-August-2018. Reese said several competitor pipelines, including Eli Lilly's (LLY), are in development for stable liquid glucagon products and the likely approval of Lilly's nasal spray glucagon should make it difficult for Xeris to reach investors' revenue expectations.

TODAY'S FREE FLY STORIES

GM

General Motors

$36.62

0.3 (0.83%)

21:16
10/23/19
10/23
21:16
10/23/19
21:16
Periodicals
Flint, Michigan UAW approves labor deal with General Motors, Bloomberg reports »

The vote was 61% in favor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

GLD

SPDR Gold Shares

$140.57

0.4 (0.29%)

20:29
10/23/19
10/23
20:29
10/23/19
20:29
Hot Stocks
SPDR Gold Shares holdings fall to 918.48MT from 919.66MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$45.74

-0.04 (-0.09%)

, CMCSK

Comcast

$0.00

(0.00%)

20:25
10/23/19
10/23
20:25
10/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$45.74

-0.04 (-0.09%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$138.39

1.19 (0.87%)

MMM

3M

$168.62

1.06 (0.63%)

NOC

Northrop Grumman

$352.89

0.48 (0.14%)

RTN

Raytheon

$203.81

-1.08 (-0.53%)

BAX

Baxter

$87.90

0.87 (1.00%)

DOW

Dow Inc.

$47.29

0.47 (1.00%)

HSY

Hershey

$149.67

-0.06 (-0.04%)

TWTR

Twitter

$38.83

0.01 (0.03%)

LUV

Southwest

$53.27

0.375 (0.71%)

TROW

T. Rowe Price

$108.01

0.01 (0.01%)

SWK

Stanley Black & Decker

$153.73

2.42 (1.60%)

HBAN

Huntington Bancshares

$14.49

0.06 (0.42%)

CTXS

Citrix

$103.60

-0.5 (-0.48%)

TSCO

Tractor Supply

$95.02

0.8 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 12

    Dec

AMZN

Amazon.com

$1,761.81

-4.26 (-0.24%)

20:22
10/23/19
10/23
20:22
10/23/19
20:22
Hot Stocks
Ceiva Logic sues Amazon for patent infringement »

CEIVA Logic announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

20:17
10/23/19
10/23
20:17
10/23/19
20:17
Earnings
Dialog Semiconductor sees Q3 revenue $409M, up from prior $360M-$400M view »

As a result of the higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBMD

Howard Bancorp

$16.20

-0.23 (-1.40%)

19:17
10/23/19
10/23
19:17
10/23/19
19:17
Earnings
Howard Bancorp reports Q3 EPS 24c, two estimates 25c »

Reports Q3 NII $17.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.93

-0.69 (-0.27%)

19:02
10/23/19
10/23
19:02
10/23/19
19:02
Hot Stocks
Tesla CFO says Model Y margins will be slightly higher than Model 3 »

Says Model Y cost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PUB

People's Utah Bancorp

$28.93

-0.57 (-1.93%)

18:58
10/23/19
10/23
18:58
10/23/19
18:58
Earnings
People's Utah Bancorp reports Q3 EPS 59c, consensus 59c »

"People's Utah…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

TSLA

Tesla

$254.93

-0.69 (-0.27%)

, MKSI

MKS Instruments

$94.65

-1.26 (-1.31%)

18:57
10/23/19
10/23
18:57
10/23/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Tesla…

TSLA

Tesla

$254.93

-0.69 (-0.27%)

MKSI

MKS Instruments

$94.65

-1.26 (-1.31%)

ALGN

Align Technology

$217.25

3.62 (1.69%)

FFIV

F5 Networks

$138.33

-0.71 (-0.51%)

MX

MagnaChip

$11.97

-0.2 (-1.64%)

PYPL

PayPal

$96.55

-0.85 (-0.87%)

LRCX

Lam Research

$233.22

-1.69 (-0.72%)

VAR

Varian Medical

$117.42

2.83 (2.47%)

NOW

ServiceNow

$220.01

-8.25 (-3.61%)

SAVE

Spirit Airlines

$37.73

0.48 (1.29%)

SEIC

SEI Investments

$57.20

-0.21 (-0.37%)

EW

Edwards Lifesciences

$224.58

2.66 (1.20%)

PTC

PTC

$66.91

1.07 (1.63%)

ORLY

O'Reilly Automotive

$400.49

-0.08 (-0.02%)

BMRN

BioMarin

$69.07

1.34 (1.98%)

CMRE

Costamare

$7.31

0.25 (3.54%)

SLM

Sallie Mae

$9.06

0.005 (0.06%)

CLB

Core Laboratories

$43.80

1.525 (3.61%)

AEM

Agnico Eagle

$54.09

1.03 (1.94%)

MSFT

Microsoft

$137.23

0.84 (0.62%)

NTGR

Netgear

$30.63

-1.32 (-4.13%)

FTI

TechnipFMC

$23.40

-0.1 (-0.43%)

EBAY

eBay

$39.22

0.25 (0.64%)

KRA

Kraton

$21.47

-0.51 (-2.32%)

F

Ford

$9.20

0.14 (1.55%)

MMLP

Martin Midstream Partners

$4.42

-0.03 (-0.67%)

XLNX

Xilinx

$93.83

-2.18 (-2.27%)

DHT

DHT Holdings

$7.68

0.3 (4.07%)

EFX

Equifax

$139.06

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

TSLA

Tesla

$254.93

-0.69 (-0.27%)

18:45
10/23/19
10/23
18:45
10/23/19
18:45
Hot Stocks
Tesla CFO says global order rate is 'strong and continues to increase' »

Says lower CapEx in Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NOW

ServiceNow

$220.01

-8.25 (-3.61%)

, NKE

Nike

$92.30

-3.31 (-3.46%)

18:44
10/23/19
10/23
18:44
10/23/19
18:44
Hot Stocks
ServiceNow CEO: I have a twenty year relationship with Nike »

In an interview on…

NOW

ServiceNow

$220.01

-8.25 (-3.61%)

NKE

Nike

$92.30

-3.31 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

TSLA

Tesla

$254.93

-0.69 (-0.27%)

18:40
10/23/19
10/23
18:40
10/23/19
18:40
Hot Stocks
Tesla CEO says self-driving 'appears to be on track' for release by year-end »

Says releasing version 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PKG

Packaging Corp.

$110.11

1.48 (1.36%)

18:40
10/23/19
10/23
18:40
10/23/19
18:40
Earnings
Packaging Corp. reports Q3 EPS ex-items $1.92, consensus $1.90 »

Reports Q3 revenue $1.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Nov

TSLA

Tesla

$254.93

-0.69 (-0.27%)

18:38
10/23/19
10/23
18:38
10/23/19
18:38
Hot Stocks
Tesla CEO says made great strides in controlling costs during Q3 »

Operating cost is lowest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

POOL

Pool Corp.

$206.03

-6.87 (-3.23%)

18:32
10/23/19
10/23
18:32
10/23/19
18:32
Hot Stocks
Pool Corp. CFO sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 13

    Nov

GOOG

Alphabet

$1,259.62

16.835 (1.35%)

, GOOGL

Alphabet Class A

$1,257.88

16.8 (1.35%)

18:29
10/23/19
10/23
18:29
10/23/19
18:29
Periodicals
Google accused of building spy software curb worker dissent, Bloomberg says »

Google workers are…

GOOG

Alphabet

$1,259.62

16.835 (1.35%)

GOOGL

Alphabet Class A

$1,257.88

16.8 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

NFBK

Northfield Bancorp

$16.88

0.04 (0.24%)

18:18
10/23/19
10/23
18:18
10/23/19
18:18
Earnings
Northfield Bancorp reports Q3 EPS 28c, consensus 26c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRP

BRP Group

$0.00

(0.00%)

18:16
10/23/19
10/23
18:16
10/23/19
18:16
Syndicate
BRP Group 16.4M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GOOG

Alphabet

$1,259.62

16.835 (1.35%)

, GOOGL

Alphabet Class A

$1,257.88

16.8 (1.35%)

18:04
10/23/19
10/23
18:04
10/23/19
18:04
Periodicals
Google accused of building spy software curb worker dissent, Bloomberg says »

Google workers are…

GOOG

Alphabet

$1,259.62

16.835 (1.35%)

GOOGL

Alphabet Class A

$1,257.88

16.8 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

MSFT

Microsoft

$137.23

0.84 (0.62%)

18:03
10/23/19
10/23
18:03
10/23/19
18:03
Hot Stocks
Microsoft sees Q2 Productivity and Business Processes revenue $11.3B-$11.5B »

Sees Q2: Intelligent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

  • 09

    Dec

TSLA

Tesla

$254.93

-0.69 (-0.27%)

18:02
10/23/19
10/23
18:02
10/23/19
18:02
Hot Stocks
Breaking Hot Stocks news story on Tesla »

Tesla up 20.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ISTR

Investar Holding

$24.00

0.01 (0.04%)

18:01
10/23/19
10/23
18:01
10/23/19
18:01
Earnings
Investar Holding reports Q3 EPS 46c, consensus 48c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MSFT

Microsoft

$137.23

0.84 (0.62%)

17:58
10/23/19
10/23
17:58
10/23/19
17:58
Hot Stocks
Microsoft says 'off to strong start' to FY20 »

Says: Investing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

  • 09

    Dec

FIBK

First Interstate

$43.01

0.34 (0.80%)

17:53
10/23/19
10/23
17:53
10/23/19
17:53
Earnings
First Interstate reports Q3 EPS 76c, consensus 79c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

MYGN

Myriad Genetics

$31.58

-0.71 (-2.20%)

, GSK

GlaxoSmithKline

$43.25

0.74 (1.74%)

17:43
10/23/19
10/23
17:43
10/23/19
17:43
Hot Stocks
Myriad Genetics announces FDA approval of myChoice CDx test »

Myriad Genetics (MYGN)…

MYGN

Myriad Genetics

$31.58

-0.71 (-2.20%)

GSK

GlaxoSmithKline

$43.25

0.74 (1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.